The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Postmenopausal Osteoporosis
Abstract
Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis are common, particularly among older women, and hip fractures can be devastating. Treatment is generally recommended in postmenopausal women who have a bone mineral density T score of -2.5 or less, a history of spine or hip fracture, or a Fracture Risk Assessment Tool (FRAX) score indicating increased fracture risk. Bisphosphonates (generic) and denosumab reduce the risk of hip, nonvertebral, and vertebral fractures; bisphosphonates are commonly used as first-line treatment in women who do not have contraindications. Teriparatide reduces the risk of nonvertebral and vertebral fractures. Osteonecrosis of the jaw and atypical femur fractures have been reported with treatment but are rare. The benefit-to-risk ratio for osteoporosis treatment is strongly positive for most women with osteoporosis. Because benefits are retained after discontinuation of alendronate or zoledronic acid, drug holidays after 5 years of alendronate therapy or 3 years of zoledronic acid therapy may be considered for patients at lower risk for fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationBone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Calcium plus Vitamin D Supplementation and the Risk of Fractures
Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., Bassford, T., Beresford, S. A. A., Black, H. R., Blanchette, P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055218 · Cited by 1,883
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Self-citationKhan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Cauley, J. A. (2003) · JAMA · doi:10.1001/jama.290.13.1729 · Cited by 1,221
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Self-citationCummings, S. R. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2445 · Cited by 699
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Self-citationBisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 512
Self-citationTrends in Fracture Incidence: A Population-Based Study Over 20 Years
Amin, S., Achenbach, S. J., Atkinson, E. J., Khosla, S., & Melton, L. J. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2072 · Cited by 400
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Compston, J., Bowring, C., Cooper, A., Cooper, C., Davies, C., Francis, R., Kanis, J. A., Marsh, D., McCloskey, E. V., Reid, D. M., et al. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.013 · Cited by 304
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?
Black, D. M., Bauer, D. C., Schwartz, A. V., Cummings, S. R., & Rosen, C. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1202623 · Cited by 279
Self-citationMurad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., Abu Elnour, N. O., Erwin, P. J., Hazem, A., Puhan, M. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3060 · Cited by 277
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
Reid, I. R., Gamble, G. D., Mesenbrink, P., Lakatos, P., & Black, D. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0597 · Cited by 257
Self-citationGedmintas, L., Solomon, D. H., & Kim, S. C. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1893 · Cited by 256
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk
Cummings, S. R., Tice, J. A., Bauer, S., Browner, W. S., Cuzick, J., Ziv, E., Vogel, V., Shepherd, J., Vachon, C., Smith-Bindman, R., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp018 · Cited by 254
Risk of Atypical Femoral Fracture during and after Bisphosphonate Use
Schilcher, J., Koeppen, V., Aspenberg, P., & Michaëlsson, K. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1403799 · Cited by 247
Jackson, R. D., Wactawski-Wende, J., LaCroix, A. Z., Pettinger, M., Yood, R. A., Watts, N. B., Robbins, J. A., Lewis, C. E., Beresford, S. A., Ko, M. G., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060312 · Cited by 239
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4118 · Cited by 187
Self-citationIncidence and demography of femur fractures with and without atypical features
Feldstein, A. C., Black, D., Perrin, N., Rosales, A. G., Friess, D., Boardman, D., Dell, R., Santora, A., Chandler, J. M., Rix, M. M., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1550 · Cited by 166
Self-citationScreening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task Force
LeBlanc, E. S., Zakher, B., Daeges, M., Pappas, M., & Chou, R. (2014) · Annals of Internal Medicine · doi:10.7326/m14-1659 · Cited by 147
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy: The FLEX Study
Bauer, D. C., Schwartz, A. V., Palermo, L., Cauley, J. A., Hochberg, M. C., Santora, A., Cummings, S. R., & Black, D. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1232 · Cited by 139
Self-citationCalcium Supplements and Fracture Prevention
Bauer, D. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1210380 · Cited by 137
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 136
Self-citationHinton, P. S., Nigh, P., & Thyfault, J. P. (2015) · Bone · doi:10.1016/j.bone.2015.06.008 · Cited by 108
Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches
Cosman, F. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0237-9 · Cited by 101
Wark, J. D., Bensen, W., Recknor, C. P., Ryabitseva, O. F., Chiodo, J., Mesenbrink, P. G., & de Villiers, T. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1563-8 · Cited by 76
Yates, C. J., Chauchard, M.-A., Liew, D., Bucknill, A., & Wark, J. D. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.01.003 · Cited by 55
Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy
Modi, A., Siris, E. S., Tang, J., & Sen, S. S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1016605 · Cited by 48
Yun, H., Curtis, J. R., Guo, L., Kilgore, M. L., Muntner, P., Saag, K. G., Matthews, R., Morrisey, M. A., Wright, N. C., Becker, D. J., et al. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-112 · Cited by 40
Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy
Richman, S. M., Edusa, V., Fadiel, A., & Naftolin, F. N. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000191205.20738.01 · Cited by 25
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Wu, A.-M., Bisignano, C., James, S. L., Abady, G. G., Abedi, A., Abu-Gharbieh, E., Alhassan, R. K., Alipour, V., Arabloo, J., Asaad, M., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00172-0 · Cited by 1,291
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
Metadata
- Authors
- Black, D. M., & Rosen, C. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-21
- Volume
- 374
- Issue
- 3
- Pages
- 254-262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1513928844
- Cited by
- 1,712
- References
- 50
- FWCI
- 123.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.